Augmentin XR

See also: Generic Augmentin ES-600

Augmentin XR is a brand name of amoxicillin/clavulanate, approved by the FDA in the following formulation(s):

AUGMENTIN XR (amoxicillin; clavulanate potassium - tablet, extended release; oral)

• 
  Manufacturer: DR REDDYS LABS INC
  
  Approval date: September 25, 2002
  
  Strength(s): 1GM;EQ 62.5MG BASE ^[RLD][AB]

Has a generic version of Augmentin XR been approved?

A generic version of Augmentin XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Augmentin XR and have been approved by the FDA:

AMOXICILLIN AND CLAVULANATE POTASSIUM (amoxicillin; clavulanate potassium tablet, extended release; oral)

• 
  Manufacturer: SANDOZ
  
  Approval date: April 21, 2010
  
  Strength(s): 1GM;EQ 62.5MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Augmentin XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Modified release pharmaceutical formulation comprising amoxycillin
  Patent 6,746,692
  Issued: June 8, 2004
  Inventor(s): Creighton P.; Conley & John A.; Roush & Kevin H.; Storm
  Assignee(s): Beecham Pharmaceuticals (Pte) Limited
  Bacterial infections may be treated using a high dosage regimen of amoxycillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
  
  Patent expiration dates:
  
  
  • April 4, 2020
    
    ✓ 
    Drug product
  
  



• 
  Composition comprising amoxicillin and potassium clavulanate
  Patent 6,783,773
  Issued: August 31, 2004
  Inventor(s): Kevin H.; Storm & Creighton P.; Conley & John A.; Roush
  Assignee(s): Beecham Pharmaceuticals (Pte) Limited
  Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
  
  Patent expiration dates:
  
  
  • April 4, 2020
    
    ✓ 
    Drug product
  
  



• 
  Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
  Patent 6,878,386
  Issued: April 12, 2005
  Inventor(s): Conley; Creighton P. & Roush; John A. & Storm; Kevin H.
  Assignee(s): Beecham Pharmaceuticals (Pte) Limited
  Bacterial infections may be treated using a high dosage regimen of amoxycillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
  
  Patent expiration dates:
  
  
  • April 4, 2020
    
    ✓ 
    Patent use: MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
  
  



• 
  Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan
  Patent 7,217,430
  Issued: May 15, 2007
  Inventor(s): Storm; Kevin H. & Conley; Creighton P. & Roush; John A.
  Assignee(s): Beecham Pharmaceuticals (Pte) Limited
  Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
  
  Patent expiration dates:
  
  
  • April 4, 2020
    
    ✓ 
    Patent use: MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
    ✓ 
    Drug product
  
  



• 
  Method of treating a bacterial infection
  Patent 7,250,176
  Issued: July 31, 2007
  Inventor(s): Storm; Kevin H. & Conley; Creighton P. & Roush; John A.
  Assignee(s): Beecham Pharmaceuticals (Pte) Limited
  Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
  
  Patent expiration dates:
  
  
  • April 4, 2020
    
    ✓ 
    Patent use: MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
  
  

See also...

• Augmentin XR Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Augmentin XR Consumer Information (Cerner Multum)
• Augmentin XR Advanced Consumer Information (Micromedex)
• Amoxicillin and Clavulanate Consumer Information (Drugs.com)
• Amoxicillin/Clavulanate Consumer Information (Wolters Kluwer)
• Amoxicillin/Clavulanate Chewable Tablets Consumer Information (Wolters Kluwer)
• Amoxicillin/Clavulanate Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Amoxicillin/Clavulanate Suspension Consumer Information (Wolters Kluwer)
• Amoxicillin and clavulanate potassium Consumer Information (Cerner Multum)
• Alti-Amoxi Clav Advanced Consumer Information (Micromedex)
• Apo-Amoxi Clav Advanced Consumer Information (Micromedex)
• Novo-Clavamoxin 125 Advanced Consumer Information (Micromedex)
• Novo-Clavamoxin 250 Advanced Consumer Information (Micromedex)
• Ratio-Amoxi Clav 250f Advanced Consumer Information (Micromedex)
• Amoxicillin and clavulanate Advanced Consumer Information (Micromedex)
• Amoxicillin and Clavulanate Potassium AHFS DI Monographs (ASHP)